Abstract
Novel series of 1-(arenesulfonyl)imidazolidin-2-one (3a-i) and 1,3-bis(arenesulfonyl)imidazolidin-2-one (5a-i) have been synthesized and tested for their antitumor activity against 60 tumor cell lines taken from nine different organs. A significant inhibition for cancer cells was observed with series 5a-i compounds compared with the series 3a-i which showed a weak inhibition. Compounds 5a-i showed good inhibitory effect at the lung cancer HOP-92 and renal cancer CAKI-1 and UO-31 cell lines. Compound 5e showed remarkable broad-spectrum antitumor activity.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Crystallography, X-Ray
-
Drug Design
-
Drug Screening Assays, Antitumor
-
Humans
-
Imidazolidines / chemical synthesis
-
Imidazolidines / chemistry*
-
Imidazolidines / pharmacology*
-
Models, Molecular
-
Neoplasms / drug therapy
-
Structure-Activity Relationship
-
Sulfonylurea Compounds / chemical synthesis
-
Sulfonylurea Compounds / chemistry
-
Sulfonylurea Compounds / pharmacology
Substances
-
Antineoplastic Agents
-
Imidazolidines
-
Sulfonylurea Compounds
-
ethylene urea